Andrew Newland is the founder and Chief Executive of ANGLE plc. For over twenty five years, he has specialised in building technology-based businesses based on strong intellectual property and for the last fifteen years he has been Chairman or on the Board of several specialist medical technology companies. Andrew has an MA in Engineering Science from the University of Cambridge, and is a qualified Chartered Accountant.
Vice President; CEO ANGLE Biosciences, Inc.
Paul Smith is the CEO of ANGLE Biosciences, Inc.. Prior to joining ANGLE, Paul most recently served as President and CEO of Axela Inc. a company specializing in the development of multiplex biomarker tools. He has more than 30 years of experience in the life science instrumentation field with a diverse background in sales, marketing and field operations.
Chief Scientific Officer
Daniel (Dan) J. O'Shannessy, Ph.D. is Chief Scientific Officer for ANGLE plc. Dan has nearly 30 years’ experience in a combination of scientific, business development and strategic planning roles within the life sciences industry, the last 20 of which have been in the clinical diagnostics arena. Most recently, Dan founded a successful consulting business (TMDx Consulting LLC) focused on the translational aspects of diagnostics with clients in both the pharmaceutical and diagnostic industries. Prior to TMDx Consulting, Dan built and headed the Translational Medicine and Diagnostics group at Morphotek, Inc. (a subsidiary of Eisai Pharmaceuticals, Inc., Tokyo) where he was responsible for the discovery and translation of diagnostics into clinical practice, with an emphasis on ovarian cancer diagnostics and therapeutics. Prior to Morphotek, Dan held several other executive management roles including Chief Operating Officer of Targeted Diagnostics & Therapeutics, Inc. (TDT, West Chester, PA), Senior Director of Strategic Planning, Oncology Diagnostics at Gen-Probe, Inc. of San Diego, California, and Chief Scientific Officer at Fujirebio Diagnostics, Inc. (FDI, Malvern, PA).
Chief Financial Officer
Ian Griffiths is the Finance Director of ANGLE plc. He has specialised in technology commercialisation for over twenty years and is an expert on the development and growth of new technology based businesses. Ian has a BSc in Mathematics with Management Applications from Brunel University and is qualified as a chartered accountant. For seven years he worked for KPMG, initially in accountancy, then in management consulting within KPMG’s High Technology Consulting Group where he specialised in financial modelling, business planning, corporate finance, market development and strategy work.
Business Development Director
Michael has extensive experience of commercialising new technologies, with a solid background in strategic and operational leadership. Michael joined ANGLE in 2009 to lead a government backed technology incubator. The incubator evaluated more than 60 early stage technology companies from around the UK before selecting the highest potential start-ups and providing intense consultancy support in setting technology milestones, developing an effective business model, building collaborations and securing early customers.
Director of Manufacturing & Regulatory Affairs
Martin is the Head of Manufacturing and Regulatory at ANGLE plc, a Chartered Engineer and holds an MEng degree in Electrical and Electronic Engineering from The University of Nottingham. He joined ANGLE in 2004 and first specialised in technology commercialisation and knowledge transfer projects supporting businesses, particularly involving universities and other specialist knowledge and research centres.
Clinical Studies Director